sur Jaguar Health, Inc. (NASDAQ:JAGX)
Magdalena Biosciences to Present at BIO CEO & Investor Conference
Magdalena Biosciences, a joint venture between Jaguar Health and Filament Health, is set to present at the BIO CEO & Investor Conference on February 10, 2025, in New York City. Dr. Karen Brunke, Acting CEO of Magdalena, will provide an overview of the company's initiatives. Magdalena is focused on developing next-generation psychoactive prescription drugs for mental health conditions, such as ADHD and schizophrenia.
Magdalena plans to submit an Investigational New Drug (IND) application in 2025 for its leading botanical drug candidate, MB2500. This candidate aims to address cognitive deficits associated with schizophrenia and ADHD. The plant-derived MB2500 shows promise due to its neuroprotective and cognitive-enhancing properties.
Jaguar Health owns approximately 40% of Magdalena. The venture intends to IND-enable 1-2 more botanical drug candidates by late 2025 or early 2026, aiming to bridge traditional plant knowledge with modern pharmaceutical development.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.